​

Evolus Stock (NASDAQ:EOLS)

ForecastRevenueOwnershipFinancialsChartTranscripts
Evolus by TradingView

Previous Close

$7.35

52W Range

$5.71 - $17.82

50D Avg

$8.15

200D Avg

$10.80

Market Cap

$485.79M

Avg Vol (3M)

$1.34M

Beta

1.07

Div Yield

-

EOLS Company Profile

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

372

IPO Date

Feb 08, 2018

Website

EOLS Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
Service$1.97M$2.36M$2.02M
Product$264.31M$199.72M$146.59M

Fiscal year ends in Dec 24 | Currency in USD

EOLS Financial Summary

Dec 24Dec 23Dec 22
Revenue$264.31M$202.09M$148.62M
Operating Income$-34.41M$-49.23M$-57.58M
Net Income$-50.42M$-61.69M$-74.41M
EBITDA$-66.15M$-41.81M$-60.72M
Basic EPS$-0.81$-1.08$-1.33
Diluted EPS$-0.81$-1.08$-1.33

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 25Aug 05, 25 | 4:30 PM
Q1 25May 07, 25 | 4:30 PM
Q4 24Mar 04, 25 | 4:30 PM

Peer Comparison

TickerCompany
CRNXCrinetics Pharmaceuticals, Inc.
SYRSSyros Pharmaceuticals, Inc.
ANIPANI Pharmaceuticals, Inc.
COLLCollegium Pharmaceutical, Inc.
SLDBSolid Biosciences Inc.
INCRInterCure Ltd.